The Effect of Improved Glycemic Control on the Composition and Function of High-Density Lipoproteins (HDL) in Patients With Type 1 Diabetes (HAGI-T1D)

April 29, 2026 updated by: Centre Hospitalier Universitaire Dijon

Effect of Improved Glycemic Control on the Composition and Function of High-density Lipoproteins (HDL) in Patients With Type 1 Diabetes: a Prospective, Single-center Study. Comparison With Non-diabetic, Non-dyslipidemic Control Subjects. - HAGI-T1D Study

The HAGI-T1D study aims to determine the effect of improved glycemic control on the composition and function of high-density lipoproteins (HDL) in patients with type 1 diabetes (T1D). It requires the establishment of a biological plasma/serum bank.

T1D patients hospitalized in the Endocrinology-Diabetology-Metabolic Diseases Department at the Dijon Bourgogne University Hospital for poorly controlled diabetes (defined by glycated hemoglobin HbA1c >8.0%).

The study includes a T1D group of 80 patients with unsatisfactory glycemic control, who will undergo intensified therapy in accordance with standard clinical practice (modification of insulin therapy, therapeutic education, and lifestyle and dietary guidelines). The study also includes a control group of 63 non-diabetic, non-dyslipidemic subjects enrolled based on the results of laboratory tests from the screening visit to assess whether improved glycemic control in the T1D group restores anti-atherogenic functions and HDL composition to a level comparable to that of the control group.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

143

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Patients with type 1 diabetes whose condition is poorly controlled

Description

Inclusion Criteria:

Control group non-diabetic and non-dyslipidemic :

  • A person who has giver written consent
  • Fasting blood glucose < 1,10 g/L
  • Triglycerides < 1,50 g/L (< 1,70 mmol/L).
  • HDL cholesterol > 1,03 mmol/L (men) or > 1,30 mmol/L (women).
  • LDL cholesterol < 1,60 g/L.

Type 1 diabetes group :

  • A person who has giver written consent
  • Treated type 1 diabetes (regardless of the route of insulin administration).
  • HbA1c > 8.0% (> 64 mmol/mol).

Exclusion Criteria:

All participants :

  • A person who is not enrolled in or eligible for a social security program
  • A person subject to a legal protective measure (guardianship, tutorship)
  • A person subject to a judicial protective measure
  • Pregnant women, women in labor, or breastfeeding women
  • Adults who are legally incompetent or unable to give informed consent
  • Minors
  • Systemic inflammatory disease
  • Medications that affect lipoprotein metabolism: immunosuppressive therapy, long-term corticosteroid therapy.

Control group non-diabetic and non-dyslipidemic :

  • Diabetes or use of an antidiabetic medication.
  • Dyslipidemia or use of lipid-lowering medication.
  • Cardiovascular disease (history of stroke, myocardial infarction, coronary artery disease).
  • Kidney disease (glomerular filtration rate CKD-EPI < 75 mL/min/1.73 m²)

  • Presence of metabolic syndrome defined by the presence of at least three of the following criteria (NCEP-ATP III criteria):

    • waist circumference > 102 cm in men, > 88 cm in women;
    • fasting triglycerides > 1.70 mmol/L ( > 1.50 g/L);
    • HDL cholesterol > 1.03 mmol/L in men and 1.29 mmol/L in women;
    • systolic blood pressure ≥ 130 mmHg and/or diastolic blood pressure ≥ 85 mmHg;
    • fasting blood glucose ≥ 6.10 mmol/L (≥ 1.10 g/L).

Type 1 diabetes group:

  • Diagnosis of type 1 diabetes within 12 months prior to enrollment.
  • Glomerular filtration rate (CKD-EPI) < 60 mL/min/1.73 m².
  • Albuminuria ≥ 30 mg/g creatinine.
  • Initiation of lipid-lowering therapy within the month prior to the study.

Exclusion criteria:

Type 1 diabetes group:

- Initiation of lipid-lowering therapy during the 3 months of the study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Patients with type 1 diabetes
Patients hospitalized in the Endocrinology, Diabetes, and Metabolic Diseases Department at the Dijon Bourgogne University Hospital due to poorly controlled diabetes.
Biological: Blood test
Performed on an empty stomach at the initial visit and then at 3 months
Biological: Urine sample
Performed only during the initial visit for patients with type 1 diabetes
Control
Patients who are neither diabetic nor hypoglycemic
Biological: Blood test
Performed on an empty stomach at the initial visit and then at 3 months

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Difference in the percentage of HDL-induced stimulation of eNOS activation via phosphorylation at serine 1177 in human HUVEC endothelial cells
Time Frame: Between Month 0 and Month 3
Between Month 0 and Month 3

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Centre Hospitalier Universitaire Dijon

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 25, 2025

Primary Completion (Estimated)

November 1, 2027

Study Completion (Estimated)

November 1, 2027

Study Registration Dates

First Submitted

April 23, 2026

First Submitted That Met QC Criteria

April 29, 2026

First Posted (Actual)

May 4, 2026

Study Record Updates

Last Update Posted (Actual)

May 4, 2026

Last Update Submitted That Met QC Criteria

April 29, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • DENIMAL AOI 2023

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Type 1 Diabetes

Clinical Trials on Blood test

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tunisia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe